{"id":56153,"date":"2026-02-03T21:34:16","date_gmt":"2026-02-03T13:34:16","guid":{"rendered":"https:\/\/flcube.com\/?p=56153"},"modified":"2026-02-03T21:34:17","modified_gmt":"2026-02-03T13:34:17","slug":"eli-lilly-mounjaro-fails-to-win-eu-approval-for-hfpef-heart-failure-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56153","title":{"rendered":"Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication"},"content":{"rendered":"\n

Eli Lilly<\/strong> (NYSE:\u202fLLY<\/a>) announced that the European Medicines Agency (EMA) drug advisory panel<\/strong> declined to recommend approval for Mounjaro (semaglutide)<\/strong> for treating heart failure with preserved ejection fraction (HFpEF)<\/strong> in adults with obesity. The panel concluded it remains uncertain whether the reduction in heart\u2011failure hospitalizations reflects a weight\u2011loss\u2011independent effect of Mounjaro.<\/p>\n\n\n\n

Regulatory Outcome & Clinical Context<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Eli Lilly (NYSE:\u202fLLY)<\/td><\/tr>
Drug<\/strong><\/td>Mounjaro (semaglutide)<\/td><\/tr>
Indication<\/strong><\/td>HFpEF with obesity<\/td><\/tr>
Regulatory Body<\/strong><\/td>EMA drug advisory panel<\/td><\/tr>
Outcome<\/strong><\/td>Approval denied<\/td><\/tr>
Reason<\/strong><\/td>Uncertainty about weight\u2011loss\u2011independent effect<\/td><\/tr>
Data Inclusion<\/strong><\/td>Study data to be included in product information<\/td><\/tr>
Clinical Trial<\/strong><\/td>HFpEF obesity trial showing hospitalization reduction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Commercial Outlook<\/h2>\n\n\n\n